Joseph Jacob, MD, MCR

Dr. Joseph Jacob, MD, MCR is a highly skilled urologist and bladder cancer specialist based in Syracuse, New York. He is affiliated with multiple hospitals in the region, including Upstate University Hospital and the Syracuse Veterans Affairs Medical Center, where he serves as the Director of Urologic Oncology. With seven years of clinical practice, Dr. Jacob specializes in surgical oncology and has extensive experience treating testicular, kidney, urinary bladder, and other urologic neoplasms. He is committed to bridging research and patient-centered care, leading clinical trials, and advancing innovative therapies in non–muscle-invasive bladder cancer (NMIBC).

Dr. Jacob earned his medical degree from The Ohio State University College of Medicine (Class of 2010). He completed a surgical internship and urology residency at Indiana University School of Medicine (2010–2015), followed by a fellowship in Minimally Invasive Urologic Surgery (2015–2017) and a Master of Clinical Research (MCR, 2015–2017) from Indiana University. This rigorous training underpins his expertise in both advanced surgical techniques and clinical research, allowing him to contribute to the development of novel therapies and procedural best practices for bladder cancer treatment.

In addition to his clinical work, Dr. Jacob is an accomplished author and thought leader. He has published multiple commentaries in Urology Times and Targeted Oncology, including a 2025 piece on TAR-200 monotherapy for BCG-unresponsive high-risk NMIBC and expert guidance on the FDA-approved intravesical gemcitabine delivery system. He has also served as principal investigator on clinical trials, including Phase 3 studies of UGN‑102 for intermediate-risk NMIBC. Through his research, publications, and leadership, Dr. Jacob continues to advance the field of urologic oncology while ensuring patients receive evidence-based, innovative care.

• Ohio State University College of Medicine

• American Board of Urology

• Regional Top Doctor Castle Connolly 2014

• American Urological Association - AUA
• Society of Urologic Oncology
• Member, Cancer Center Clinical Management and Operations Committee

In 2025, Dr. Jacob authored a commentary titled “TAR-200 monotherapy in patients with BCG‑unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) carcinoma in situ: 1-year durability and patient-reported outcomes from SunRISe-1” for Urology Times. He is also listed as an author on several other 2025 pieces in Urology Times, including “Final Thoughts and Clinical Trials in NMIBC”, “Uptake of New Treatments in Urology Practice”, and “Patient Communication and Treatment Adherence in NMIBC”. Additionally, Dr. Jacob wrote an expert commentary for Targeted Oncology on the FDA‑approved intravesical gemcitabine delivery system (formerly TAR‑200) titled “Gemcitabine Intravesical System Changes the Paradigm of Bladder Cancer Treatment” and has appeared in media discussions on its clinical potential in NMIBC for OncLive. Beyond his publications, Dr. Jacob serves as the principal investigator on multiple clinical trials at Upstate Medical University, including a Phase 3 study of UGN‑102 for intermediate-risk NMIBC.